BIOMARKER:

MET positive

Entrez ID:

Related biomarkers:

‹

›

MET positive MET positive	Solid Tumor Solid Tumor	MET positive MET positive	Solid Tumor Solid Tumor	GST-HG16 Sensitive: C2 – Inclusion Criteria	GST-HG16 Sensitive: C2 – Inclusion Criteria
MET positive MET positive	Non Small Cell Lung Cancer NSCLC	MET positive MET positive	Non Small Cell Lung Cancer NSCLC	ABBV-399 Sensitive: C2 – Inclusion Criteria	ABBV-399 Sensitive: C2 – Inclusion Criteria
MET positive MET positive	Squamous Cell Carcinoma of Head and Neck SCCHN	MET positive MET positive	Squamous Cell Carcinoma of Head and Neck SCCHN	nivolumab Resistant: C3 – Early Trials	nivolumab Resistant: C3 – Early Trials
MET positive MET positive	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	MET positive MET positive	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials	erlotinib + ABBV-399 Sensitive: C3 – Early Trials
MET positive MET positive	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	MET positive MET positive	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	erlotinib + ABBV-399 Sensitive: C3 – Early Trials	erlotinib + ABBV-399 Sensitive: C3 – Early Trials
MET positive MET positive	Non Small Cell Lung Cancer NSCLC	MET positive MET positive	Non Small Cell Lung Cancer NSCLC	erlotinib + LY2875358 Sensitive: C3 – Early Trials	erlotinib + LY2875358 Sensitive: C3 – Early Trials
MET positive MET positive	Gastric Cancer Gastric Cancer	MET positive MET positive	Gastric Cancer Gastric Cancer	c-MET-targeted CAR-T immunotherapy Sensitive: D – Preclinical	c-MET-targeted CAR-T immunotherapy Sensitive: D – Preclinical